HR7212-119

What This Bill Does

The Hemp Enforcement, Modernization, and Protection Act creates a new FDCA chapter for cannabinoid hemp products rather than leaving hemp-derived cannabinoids in a lightly defined space. It defines cannabinoids and cannabinoid hemp products, excludes those products from some drug and dietary-supplement terminology, and assigns FDA authority over products made, packed, distributed, labeled, imported, or held for U.S. consumption. It deems products adulterated for contamination, excess cannabinoid content, risky additives such as alcohol, caffeine, tobacco, nicotine, or melatonin, use in food-producing animals, unsafe food additives, or drug-like risks. It deems products misbranded for false or misleading labels, advertisements, missing manufacturer contact information, missing serving and cannabinoid-content disclosures, allergen-related disclosures, and other FDA-required warnings. Oral, inhalable, and topical products receive separate serving, package, labeling, tamper-evident, child-safety, pesticide, terpene, flavoring, ingredient, and content-limit rules. Facilities must register and list products, foreign facilities can be inspected or refused admission, responsible persons can be ordered to stop distribution and recall dangerous products, FDA must issue content-threshold rules with fallback thresholds if it misses the deadline, and an advisory committee gives FDA technical and public input.

Who Benefits and How

Consumers of cannabinoid hemp products benefit from clearer safety rules, content limits, front-of-package identification, adverse-event concepts, recall authority, and foreign-inspection controls. Responsible manufacturers, packers, distributors, importers, testing laboratories, and retailers benefit from a lawful national compliance pathway that can distinguish compliant products from contaminated, mislabeled, or high-risk competitors. FDA and HHS gain a statutory framework for orders, inspections, records, recalls, product listings, and advisory-committee advice.

Who Bears the Burden and How

Cannabinoid hemp product manufacturers, packers, distributors, importers, labelers, domestic facilities, foreign facilities, testing laboratories, and responsible persons must register facilities, list products, substantiate labels, meet manufacturing and testing standards, obey oral, inhalable, and topical product limits, maintain records, cooperate with FDA inspections, and carry out recalls. FDA staff must write rules and orders, run registration and product listing systems, inspect records and foreign facilities, enforce prohibited acts, convene a 16-member advisory committee, and set content thresholds under deadline pressure.

Key Provisions

• Adds FDCA definitions for cannabinoids, cannabinoid hemp products, derivatives, facilities, responsible persons, adverse events, and serious adverse events.
• Creates adulteration rules for contamination, excess cannabinoid content, unsafe additives, animal-use restrictions, unsafe food additives, and drug-like risks.
• Creates misbranding rules for false labels or advertising, manufacturer contact information, serving size, ingredient, allergen, warning, and cannabinoid-content disclosures.
• Sets oral product serving, package, label-panel, tamper-evident, and child-safety controls.
• Sets inhalable product restrictions for pesticide residues, added terpenes, flavoring agents, non-cannabis ingredients, and concentration limits.
• Sets topical product package-content, labeling, tamper-evident, and child-safety controls.
• Requires uniform manufacturing, testing, facility registration, product listing, record inspection, and foreign-facility inspection systems.
• Creates mandatory recall authority, content-threshold rulemaking with fallback limits, an FDA advisory committee, and prohibited-act enforcement.